NICE (the National Institute for Health and Care Excellence) has recently issued draft guidance recommending that Pembrolizumab (Keytruda) not be used by the NHS in England for adults with platinum-resistant, epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to two lines of chemotherapy.
We understand that this will be disappointing news for many members of our community. However, this is not a final decision, and we have the opportunity to submit evidence to NICE to challenge this proposal.
To help us ensure patients’ voices are taken into account, please take a couple of minutes to complete this short survey -particularly if you have a platinum-resistant ovarian cancer. All comments received will be anonymised before being shared with NICE.
Our specialist nurses are here for you if you have any questions or concerns about this or anything else related to ovarian cancer. Call them on 0808 802 6000 or email support@targetovariancancer.org.uk. If you have any questions about the survey, you can contact the campaigns team on campaigns@targetovariancancer.org.uk.